Pipeline

Otonomy’s mission is to develop and commercialize therapeutics to address the significant unmet medical needs in the otology market.

Product Candidate
Investigational Indication
Preclinical Phase 1 Phase 2 Phase 3 Registration
OTIPRIO®
(ciprofloxacin otic suspension)
*
Acute otitis externa (“swimmer’s ear”)

73.5%

OTIPRIO
(ciprofloxacin otic suspension)
*
Acute otitis media with tubes (AOMT)

57%

OTO-104
(dexamethasone)

Ménière’s disease

65%

OTO-104 (dexamethasone)
Cisplatin-induced hearing loss in pediatrics

50%

OTO-311
(gacyclidine)

Tinnitus

33%

OTO-4XX
Sensorineural hearing loss

11%

For additional information about Otonomy’s delivery technology, click here.

*The safety and efficacy of OTIPRIO for these uses has not been established and is under clinical investigation.